It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
EPS at Rs 32.19
Substantial reduction in losses
Subscribe To Our Newsletter & Stay Updated
